"India and China alone represent about a quarter of the worlds adult obese population, and the availability of generic semaglutide will be a big shift in how these countries manage these populations." The market is ripe in countries where semaglutide goes off patent next year, as close to one-third of the worlds adults with obesity live in those countries, says Aurelio Arias, director of thought leadership at Iqvia, a health-information company
Seiwerth, S., Brcic, L., Vuletic, L
Anyone on blood-pressure-active medications BPC-157 affects nitric oxide signaling in animal models
If you're on a 1ml weekly protocol and seeing no measurable change after six weeks, the problem is almost never 'too low a dose.' It's either formulation quality (underdosed methionine or choline), dietary interference (you're in maintenance calories, not deficit), or liver saturation (you're already consuming high dietary methionine and adding more doesn't shift the pathway further)
Neuropsychopharmacology 2017;42:147179 White B